
What smart money is saying about Inspire Medical Systems Inc
1 fund in our archive has pitched Inspire Medical Systems Inc, most recently Artisan Non-U.S. Small-Mid Growth Strategy in March 2026.
Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, a closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.
Get an email when a fund buys, sells or pitches it
Position history
Between Q3 2025 and Q1 2026, 5 fund letters reported a position in Inspire Medical Systems Inc, with 3 sells (trimmed or exited).
| Quarter | Letters | Bought | Sold | Theses |
|---|---|---|---|---|
| Q1 2026 | 0 | 0 | 0 | 1 |
| Q3 2025 | 5 | 0 | 3 | 0 |
Bought and Sold count moves: the same sentence published by several funds of one house in a quarter counts once.
Fund activity · 5 positions · 4 moves
- TrimmedHeadwaters CapitalSeptember 2025
“Top Detractor: Inspire Medical (“INSP”) -43%.”
Inspire Medical Systems Inc - September 2025
“We ended our investment campaigns in Inspire Medical Systems, Astera Labs and Clearwater Analytics during the quarter. Inspire Medical Systems is the US leader in hypoglossal nerve stimulation for sleep apnea, offering the only FDA-approved alternative to continuous positive airway pressure treatment. In late 2024, we reduced our position in Inspire from the CropSM to the GardenSM due to growing concerns about emerging competitive products. At the time, we believed that the newly launched Inspire V system would bring the company only to parity with some of these entrants, making flawless execution of the rollout essential. This quarter, it became clear that the company is facing significant challenges with the launch. As a result, we exited our GardenSM position.”
Inspire Medical Systems Inc - September 2025
“Notable detractors from relative performance during the period were Inspire Medical, MGP Executive Summary • The Fund underperformed its benchmark due to stock selection. • Inspire Medical (INSP), MGP Ingredients (MGPI), and Knife River (KNF) were three prominent detractors that impacted relative performance. • Medpace Holdings, Inc. (MEDP), AAR (AIR), and nVent Electric (NVT) were three prominent contributors to relative performance. • The Fund added Patrick Industries (PATK) and Trex Company, Inc. (TREX), during the third quarter. The Fund also started a position in James Hardie Industries (JHX) after the company’s acquisition of our long-term holding, AZEK Company (AZEK). • Small cap stocks are trading at a significant discount, despite signs of earnings growth estimate stabilization, which presents an attractive opportunity for investors focused on the long term. Third Quarter Results September 30, 20255Small Cap Fund | MSCFX Chris D. Strom Mike C. Marzolf Andrew R. Adams Co-Manager Lead Manager Co-Manager Left Middle Right Ingredients, and Knife River. Inspire Medical had a difficult quarter due to challenges related to GLP-1 usage increases, as well as rolling out a new product version, and delays with billing software and reimbursement codes.”
Inspire Medical Systems Inc - September 2025
“Offsetting that was a -38% partial quarter loss from Inspire Medical Systems, which develops medical equipment to treat obstructive sleep apnea. We had been optimistic about the rollout of its newest generation device, but Inspire had difficulty executing that earlier this year. Those problems persisted, so we exited the position.”
Inspire Medical Systems Inc - September 2025
“Offsetting that was a -39% partial quarter loss from Inspire Medical Systems Inc., which develops medical equipment to treat obstructive sleep apnea. We had been optimistic about the rollout of its newest generation device, however Inspire had difficulty executing that earlier this year. Those problems persisted, so we exited the position.”
Inspire Medical Systems Inc
Also mentioned · 1
These funds discuss Inspire Medical Systems Inc as a competitor, benchmark or comparable, without disclosing a position in it.
- June 2026
“We believe the growing sleep apnea market will be a two-player race between LivaNova and Inspire, another portfolio holding, and both have long runways for technological advancement, including AI-enabled devices.”
Inspire Medical Systems Inc
Fund coverage · 1 thesis
Inspire Medical Systems is a leader in sleep apnea implants with strong margins, recovering procedures, attractive valuation reset, and a long runway for technology and adoption.
Read the full thesis
Read every full thesis on Inspire Medical Systems Inc
Read all 1 thesis in full, with each fund's reasoning, and get unlimited access to the archive.
View plans→